Houston medical institutions launch $6M kidney research incubator

NIH funding

Houston institutions have landed $6.25 million in NIH funding to launch the HAI-KUH research training program. Photo via UH.

Institutions within Houston’s Texas Medical Center have launched the Houston Area Incubator for Kidney, Urologic and Hematologic Research Training (HAI-KUH) program. The incubator will be backed by $6.25 million over five years from the National Institutes of Health and aims to create a training pipeline for researchers.

HAI-KUH will include 58 investigators from Baylor College of Medicine, Texas Children’s Hospital, the University of Texas Health Science Center at Houston, University of Houston, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University and Texas A&M University Institute of Biosciences and Technology. The program will fund six predoctoral students and six postdoctoral associates. Trainees will receive support in scientific research, professional development and networking.

According to the organizations, Houston has a high burden of kidney diseases, hypertension, sickle cell disease and other nonmalignant hematologic conditions. HAI-KUH will work to improve the health of patients by building a strong scientific workforce that leverages the team's biomedical research resources to develop research skills of students and trainees and prepare them for sustained and impactful careers. The funding comes through the National Institute of Diabetes and Digestive and Kidney Diseases.

The principal investigators of the project include Dr. Alison Bertuch, professor of pediatric oncology and molecular and human genetics at BCM; Peter Doris, professor and director of the Institute of Molecular Medicine Center for Human Genetics at UT Health; and Margaret Goodell, professor and chair of the Department of Molecular and Cellular Biology at Baylor.

“This new award provides unique collaborative training experiences that extend beyond the outstanding kidney, urology, and hematology research going on in the Texas Medical Center,” Doris said in a news release. “In conceiving this award, the National Institute of Diabetes and Digestive and Kidney Diseases envisioned trainee development across the full spectrum of skills required for professional success.”

Jeffrey Rimer, a professor of Chemical Engineering, is a core investigator on the project and program director at UH. Rimer is known for his breakthroughs in using innovative methods in control crystals to help treat malaria and kidney stones. Other co-investigators include Dr. Wolfgang Winkelmeyer (Baylor), Oleh Pochynyuk (UTHealth), Dr. Rose Khavari (Houston Methodist) and Pamela Wenzel (UT Health).

“This new NIH-sponsored training program will enable us to recruit talented students and postdocs to work on these challenging areas of research,” Rimer added in a release.

From Your Site Articles
A new AI tool from a Baylor College of Medicine Lab could help better diagnose specific types of autism spectrum disorder, epilepsy and developmental delay disorders. Photo via Getty Images.

Houston lab develops AI tool to improve neurodevelopmental diagnoses

developing news

One of the hardest parts of any medical condition is waiting for answers. Speeding up an accurate diagnosis can be a doctor’s greatest mercy to a family. A team at Baylor College of Medicine has created technology that may do exactly that.

Led by Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, the scientists have developed an artificial intelligence-based approach that will help doctors to identify genes tied to neurodevelopmental disorders. Their research was recently published the American Journal of Human Genetics.

According to its website, Dhindsa Lab uses “human genomics, human stem cell models, and computational biology to advance precision medicine.” The diagnoses that stem from the new computational tool could include specific types of autism spectrum disorder, epilepsy and developmental delay, disorders that often don’t come with a genetic diagnosis.

“Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered,” Dhindsa said in a news release.

Typically, scientists must sequence the genes of many people with a diagnosis, as well as people not affected by the disorder, to find new genes associated with a particular disease or disorder. That takes time, money, and a little bit of luck. AI minimizes the need for all three, explains Dhindsa: “We used AI to find patterns among genes already linked to neurodevelopmental diseases and predict additional genes that might also be involved in these disorders.”

The models, made using patterns expressed at the single-cell level, are augmented with north of 300 additional biological features, including data on how intolerant genes are to mutations, whether they interact with other known disease-associated genes, and their functional roles in different biological pathways.

Dhindsa says that these models have exceptionally high predictive value.

“Top-ranked genes were up to two-fold or six-fold, depending on the mode of inheritance, more enriched for high-confidence neurodevelopmental disorder risk genes compared to genic intolerance metrics alone,” he said in the release. “Additionally, some top-ranking genes were 45 to 500 times more likely to be supported by the literature than lower-ranking genes.”

That means that the models may actually validate genes that haven’t yet been proven to be involved in neurodevelopmental conditions. Gene discovery done with the help of AI could possibly become the new normal for families seeking answers beyond umbrella terms like “autism spectrum disorder.”

“We hope that our models will accelerate gene discovery and patient diagnoses, and future studies will assess this possibility,” Dhindsa added.

Research from Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital will help develop targeted treatments for individuals with auditory disorders. Photo via Getty Images.

Houston scientists make breakthrough in hearing science and treatment research

sounds good

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital have successfully mapped which cell populations are responsible for processing different types of sounds.

Working with a team at the Oregon Health & Science University, the Houston scientists have classified where in the cochlear nucleus our brains connect with various sounds, including speech and music. The research was published in the new edition of Nature Communications.

“Understanding these cell types and how they function is essential in advancing treatments for auditory disorders,” Matthew McGinley, assistant professor of neuroscience at Baylor, said in a release. “Think of how muscle cells in the heart are responsible for contraction, while valve cells control blood flow. The auditory brainstem operates in a similar fashion — different cell types respond to distinct aspects of sound.”

Though scientists have long thought that there are distinct types of cells in the cochlear nucleus, they didn’t have tools to distinguish them until now.

Lead author on the study, Xiaolong Jiang, associate professor of neuroscience at Baylor, added: “This study not only confirms many of the cell types we anticipated, but it also unveils entirely new ones, challenging long-standing principles of hearing processing in the brain and offering fresh avenues for therapeutic exploration.”

Jiang and his team have cooked up a comprehensive cellular and molecular atlas of the cochlear nucleus, which will help them to create more targeted and more effective treatments for patients struggling with their hearing.

The strategies that aided them in creating these tools included single-nucleus RNA sequencing, which made it possible to define neuronal populations on a molecular level. Phenotypic categorizations of the cells were made possible with patch sequencing.

This is a watershed moment for the development of targeted treatments for individuals with auditory disorders, including those with impaired function in the auditory nerve, for whom cochlear implants don’t work.

“If we can understand what each cell type is responsible for, and with the identification of new subtypes of cells, doctors can potentially develop treatments that target specific cells with greater accuracy,” McGinley explains. “These findings, thanks to the work of our collaborative team, make a significant step forward in the field of auditory research and get us closer to a more personalized treatment for each patient.”

The University of Texas MD Anderson Cancer Center was recognized for advancements in electronic functionality, AI and robotics. Photo via mdanderson.org

Houston hospital named among smartest in the nation

hi, tech

Houston hospitals are chock-full of smart people. But they’re also equipped with lots of “smart” technology. In fact, five local hospitals appear on Newsweek’s new list of the world’s best “smart” hospitals.

To compile the list, Newsweek teamed up with data provider Statista to rank the world’s top 330 hospitals for the use of smart technology. The ranking factors were electronic functionality, telemedicine, digital imaging, artificial intelligence (AI), and robotics.

The highest-ranked Houston hospital is the University of Texas MD Anderson Cancer Center, appearing at No. 6. The hospital was recognized for advancements in electronic functionality, AI and robotics.

“MD Anderson has a significant opportunity and a responsibility to our many stakeholders to create a digital ecosystem that promotes collaboration and advances scientific discovery to enhance patient outcomes,” David Jaffray, the cancer center’s chief technology and digital officer, said in a 2021 news release.

“Through our ongoing focus on enabling the use of new technologies to place quantitative data in context for our researchers,” Jaffray added, “we foster cutting-edge oncology data science to inform our cancer discovery research and to accelerate translation of our research findings into benefits for cancer patients.”

Ahead of MD Anderson on the list are:

  1. Mayo Clinic in Rochester, Minnesota.
  2. Cleveland Clinic in Cleveland.
  3. Massachusetts General Hospital in Boston.
  4. Johns Hopkins Hospital in Baltimore.
  5. Mount Sinai Hospital in New York City.

Other Houston hospitals on the list are:

  • Houston Methodist Hospital, No. 11.
  • Baylor St. Luke’s Medical Center, No. 105.
  • Texas Children’s Hospital, No. 197.
  • Memorial Hermann-Texas Medical Center, No. 266.
CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

University of Houston-founded company secures $2.5M in NIH grant funding

all in the timing

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

Baylor College of Medicine's Jessica Watts, Dr. Jerome Pollet, and Dr. Paul Ling with Tess. Photo by Jackelin Reyna/Houston Zoo

Houston med school develops revolutionary mRNA vaccine for elephants

zoology biology

An innovative team from Baylor College of Medicine and Texas Children’s Hospital has worked with the Houston Zoo to develop a first-of-its-kind treatment for elephants, which has been administered to its first patient.

Tess, the beloved, 40-year-old matriarch of the Houston Zoo’s elephant herd, is recovering well after receiving the first-ever mRNA vaccine against elephant endotheliotropic herpesvirus (EEHV) 1A on Tuesday, June 18. The veterinary staff at the Houston Zoo will monitor Tess in the coming weeks to check her reaction and the efficacy of the vaccine.

EEHV 1A is a deadly infection for Asian Elephants. While generally benign in African Elephants, Asian Elephants can develop fatal hemorrhages. The fatality rate is a whopping 80 percent, making it one of the most serous threats to elephant populations outside of humans.

Anti-viral drugs have some effect on the disease, but two-thirds show no improvement. This has led to a search for a vaccine. For 15 years, the Houston Zoo and Dr. Paul Ling at Baylor College of Medicine’s Department of Virology and Microbiology have partnered to develop the drug. They have been helped by worldwide research from zoos and animal specialists, as well as graduate student Jessica Watts and Dr. Jeroen Pollet at Houston's Texas Children’s Hospital. The research has been funded by private donations, research partnerships, and grants.

Before being inoculated, the mRNA vaccine was exhaustively tested, with the dosage being extrapolated from data involving horses.

Houston Zoo veterinarians will periodically test Tess to see if she is developing the appropriate antibodies. If she is and there are no adverse reactions, the next step will be to administer the vaccine to the rest of the Houston herd. Many of these are Tess’s own children (Tucker, Tupelo, Tilly, and Teddy) and grandchildren (Winnie).

Should the vaccine prove effective, the doses will be made available worldwide to zoos and private elephant sanctuaries. It is likely to have a significant benefit on protecting and preserving the Asian Elephant population. As of January, there are fewer than 50,000 of the animas left in the wild. They are currently listed as endangered, and breeding programs and research done through the Houston Zoo are essential to keeping the animals from going extinct.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Shipley Donuts launches AI-powered ordering assistant

fresh tech

Popular Houston-born doughnut chain Shipley Donuts has added a first-of-its-kind AI-powered assistant to its online ordering platform.

The new assistant can create personalized order recommendations based on individual or group preferences, according to a news release from the company. Unlike standard chatbox features, the new assistant makes custom recommendations based on multiple customer factors, including budgetary habits, individual flavor preferences and order size.

"We're not just adding AI for the sake of innovation — we're solving real customer pain points by making ordering more intuitive, personalized and efficient," Kerry Leo, Shipley Vice President of Technology, said in the release.

The system also works for larger events, as it can make individual orders and catering recommendations for corporate events and meetings by suggesting quantities and assortments based on group size, event type and budget.

According to Shipley, nearly 1 in 4 guests have completed orders with the new AI technology since it launched on its website.

“The integration of the AI ordering assistant into our refreshed website represents a significant leap forward in how restaurant brands can leverage technology to enhance the customer experience,” Leo added in the release.

Houston company wins AHA competition for pediatric heart valve design

winner, winner

Houston-based PolyVascular, which develops minimally invasive solutions for children with congenital heart disease, was named the overall winner of the American Heart Association’s annual Health Tech Competition earlier this month.

The company was founded in 2014 by Dr. Henri Justino and Daniel Harrington and was part of TMCi's 2017 medical device cohort. It is developing the first polymer-based transcatheter pulmonary valve designed specifically for young children, allowing for precise sizing and redilation as the child grows while also avoiding degradation. PolyVascular has completed preclinical studies and is working toward regulatory submissions, an early feasibility study and its first-in-human clinical trial thanks to a recent SBIR grant from the National Heart, Lung, and Blood Institute.

With the new AHA honor, PolyVascular will be invited to join the association’s Center for Health Technology & Innovation Innovators’ Network, which connects entrepreneurs, providers and researchers to share and advance innovation in cardiovascular and brain health.

“This is a tremendous honor for PolyVascular—we’re especially proud to bring hope to families and children living with congenital heart defects,” Justino said in a news release. “Our technology—a minimally invasive valve that can be expanded over time to grow with the child—has the potential to dramatically reduce the need for repeated open-heart surgeries.”

The Health Tech Competition is a live forum for health care innovators to present their digital solutions for treating or preventing cardiovascular diseases and stroke.

Finalists from around the world addressed heart failure, hypertension, congenital heart defects and other issues that exist in cardiovascular, brain and metabolic health. Solutions were evaluated on the criteria of validity, scientific rigor and impact.

The judges included Texas-based Dr. Eric D. Peterson, professor of medicine in the division of cardiology at UT Southwestern Medical Center, and Dr. Asif Ali, clinical associate professor of cardiovascular medicine at the University of Texas Medical School in Houston and director at Cena Research Institute.

According to the American Heart Association, nearly half of U.S. adults live with some form of cardiovascular disease or stroke.

“The American Heart Association plays a pivotal role in advancing innovative care pathways, and we’re excited that our solution aligns with its guidelines and mission,” Justino said in a news release. “It’s time these life-changing technologies reach the youngest patients, just as they already do for adults.”

EO Houston is where ambitious founders go to scale smarter

Don't Go It Alone

Scaling a business from early traction into true growth is one of the most exciting — and punishing — chapters of entrepreneurship. Houston founders know this better than most. Our city is built on ambition: fast-moving industries, talent from around the world, and opportunities that expand as large as the Texas sky.

But as many entrepreneurs eventually learn, scaling isn’t simply “more of what worked.” It requires new systems, new thinking, and often, a new version of the founder. Even the most capable founders eventually face decisions, pressures, and turning points that only other entrepreneurs can truly understand.

Entrepreneurs’ Organization, a global peer-to-peer network of more than 18,000 business owners across 220 chapters in 75+ countries, exists for exactly this stage. One of the largest chapters in the organization, EO Houston brings that global community to life locally, offering founders the connection, learning, and accountability needed to grow sustainably and to grow up as leaders.

A community where founders learn at the highest level
The real value of EO emerges in the lived experiences of other entrepreneurs. When Houston-area founders talk about the moments growth nearly broke their companies, a universal theme appears: you can’t do it alone.

EO Houston member Robert De Los Santos of Sky High Party Rentals learned this the hard way when rapid post-COVID growth made expansion feel limitless — until it wasn’t.

“After COVID, we doubled every year and assumed inventory was the limit. In 2023 we overbought, only to realize demand had peaked. That taught us a hard truth: growth in one city has ceilings. Expanding into Austin and Dallas — the Texas Triangle — gave us new markets to put our inventory to work while we figured out how to penetrate Houston better. The challenge shifted from a strategy of ‘buy more units for demand’ to learning how to tackle the challenges of ‘leading across cities.’”

Founders often enter EO exhausted from trying to maintain control as things grow more complex. Many discover, like Jarred King of Summit Firms, that scaling requires the difficult shift from doing everything to building the team that can.

“We grew quickly because of my network, relationships, and hustle… but I was doing all the work,” King says. “I realized at that point you have to delegate — not just busy work, but important decisions to your key team, as well as set up really effective SOPs.”

“The uncomfortable truth is that you are no longer the best person for most jobs in your company," agrees Darren Randle of Houston Tents & Events. "Your inability to delegate or hire people smarter than you in key leadership and management level roles will become the single biggest drag on the entire business. You have to accept that your original 'hustle' is now a scalability risk."

Making hard decisions, such as walking away from customers or contracts, can feel like less of a sting when you know others have also been faced with tough choices. Aaron Gillaspie of West U's My Salon Suite recalls, “You can’t be everything to everyone, it’s ok to say no, and just understand some customers aren’t the right fit. It’s a two way street and both must win.”

Perspective is perhaps the most important reality check that members find at EO.

“Bigger volume will not make problems go away — you just got to get used to walking the tightrope," says Roger Pombrol of Emerald Standard. "Develop a system for good balance and do not freak out. Scared is no way to live your life. It’s ok if you fall. Your family will still love you. Money is just money. Love is love. The world tries to make you conflate them, but don’t."

Actionable insights from entrepreneurs who’ve already scaled
Conversations like these are happening every month inside EO Forum Meeting. Each EO chapter is divided into several small Forums. These confidential, committed group of 7–10 entrepreneurs who meet to share the real five percent of what they’re experiencing. It’s not advice, but experience — shared candidly, respectfully, and with the kind of vulnerability that leads to breakthroughs.

What makes Forum so impactful is the honesty it draws out. Entrepreneurs are often surrounded by employees, partners, and even family members who rely on them for answers, but seldom do they have a group where vulnerability is not only welcomed, but expected.

Learning experiences that match your ambition
EO supports that growth far beyond peer groups. Through the organization’s global partnerships with institutions like Harvard, Oxford, and INSEAD, Houston members gain access to executive-level learning experiences designed specifically for entrepreneurs.

These programs help founders step out of the day-to-day and think strategically about competitive advantage, innovation, and organizational leadership. Paired with ongoing learning through EO Jumpstart, Nano Learning, and its global library of member-created content, founders stay informed, challenged, and ahead of emerging trends.

And through global communities — ranging from EO Women and EO Under 35 to industry-specific groups — Houston members tap into expertise that spans continents and sectors. Whether someone is navigating M&A, exploring international expansion, or integrating new technologies, the right perspectives are always within reach.

What truly distinguishes EO Houston, however, is its culture. Houston’s entrepreneurial landscape is uniquely diverse and resilient, filled with founders who are hungry to build, innovate, and elevate the city’s business community. EO Houston amplifies that spirit, creating relationships that are as supportive as they are strategic. Many members describe the chapter not simply as a network, but as a catalyst for becoming better leaders, better thinkers, and — just as importantly — better human beings.

Your next level starts here
For entrepreneurs who are ready to scale—beyond their first million, beyond their current comfort zone, and toward a future that requires sharper leadership and stronger community—EO Houston offers an unmatched platform. It is a place where ambitious founders grow faster, think bigger, and gain the confidence to take bold next steps.

If you’re ready to elevate your business and your leadership alongside people who understand the journey, EO Houston is ready to welcome you. Your next level starts with the peers who can help you reach it. Learn more and become a member here.

View All Listings